Non-viral vectors for gene-based therapy

Purpose: Gene-based therapy has potential to treat a wide range of diseases, but clinical success is limited by delivery barriers. Viral vectors, while efficient, carry risks of carcinogenesis, immunogenicity, broad tropism, limited packaging capacity, and manufacturing difficulties. Non-viral vectors offer improved safety, larger payload capacity, and easier synthesis, but have low delivery efficiency relative to viruses. Advances in material sciences, nanotechnology, and nucleic acid chemistry are yielding promising non-viral delivery systems.

Hypothesis: No formal experimental hypothesis. Central thesis: non-viral vectors—lipids, polymers, conjugates, and inorganic nanoparticles—can overcome extracellular and intracellular barriers to deliver DNA, mRNA, siRNA, and miRNA therapeutics, and recent advances in materials science and nucleic acid chemistry are enabling clinical translation, particularly for siRNA delivery.

Aims: Summarize biological barriers and challenges to systemic delivery of nucleic acids. - Discuss how non-viral vectors can overcome obstacles in in vivo delivery of DNA, mRNA, siRNA, and miRNA mimics. - Highlight clinical trials that indicate the value of non-viral vectors in gene-based therapy. - Briefly comment on the potential use of non-viral vectors for systemic delivery of genome editing systems (ZFNs, TALENs, CRISPR-Cas).

Delivery system: Lipid-based vectors: cationic lipids (DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DLinDMA, DLin-MC3-DMA, DLin-KC2-DMA), neutral helper lipids (DSPC, DOPE, cholesterol), PEGylated lipids (PEG-C-DMA, PEG-DSPE), SNALP (stable nucleic acid-lipid particles), AtuPLEX, DOPC liposomes, GAP-DMORIE-DPyPE, GL67A-DOPE-DMPE-PEG, DOTAP-cholesterol. - Polymeric vectors: poly(L-lysine) (PLL), polyethyleneimine (PEI) (linear and branched), PEG-PEI, PEG-PEI-cholesterol, poly[(2-dimethylamino)ethyl methacrylate] (pDMAEMA), poly(β-amino esters), chitosan, β-cyclodextrin-containing polycations (CDP), PAMAM dendrimers, poloxamer CRL1005-benzalkonium chloride, PBAVE (membrane-destabilizing polymer). - Conjugate systems: Dynamic PolyConjugates (DPCs), GalNAc-siRNA conjugates, cholesterol-siRNA, siRNA-GalNAc conjugates. - Payloads: plasmid DNA, mRNA (modified and unmodified), siRNA, miRNA mimics, ZFN mRNA/DNA, TALEN mRNA/DNA, CRISPR-Cas9 mRNA/sgRNA, self-amplifying mRNA. - Targeting/functionalization: GalNAc (asialoglycoprotein receptor), transferrin, PEGylation (steric shielding), cholesterol, APOE-dependent targeting, mannose, ligands for receptor-mediated endocytosis. - Routes: intravenous, subcutaneous, intraperitoneal, intramuscular, intranasal, intratumoral, aerosol.

Approach: Comprehensive review of preclinical and clinical literature; no primary experiments. In vitro systems include various mammalian cell lines and primary cells. In vivo models include mice (tumor models, hereditary tyrosinemia, haemophilia, myocardial infarction, HBV replication, Ebola), rats, rabbits, cynomolgus monkeys, and nonhuman primates. Clinical trials cover siRNA (ALN-RSV01, CALAA-01, ALN-VSP02, ALN-PCS02, ALN-TTR02/Patisiran, ALN-TTRsc, ARC-520, TKM-080301, Atu027, siRNA-EphA2-DOPC), DNA vaccines (DOTAP-Chol-fus1, pGM169/GL67A, BC-819/PEI, EGEN-001, DermaVir), and miRNA mimic (MRX34).

Key methods: Review-level synthesis of: - Nanoparticle characterization: size, zeta potential, morphology (TEM, cryo-TEM), pKa. - Cellular uptake and trafficking: flow cytometry, confocal microscopy, endosomal escape, RISC loading. - Gene expression/knockdown: luciferase, EPO, GFP, qPCR, Western blot. - In vivo efficacy: tumor growth inhibition, survival, viral challenge protection, serum protein levels. - Biodistribution and pharmacokinetics: organ accumulation, circulation time, renal clearance. - Safety: immunogenicity, cytotoxicity, inflammatory responses.

Key results: ALN-PCS02 (LNP-siRNA targeting PCSK9): Phase I trial showed substantial reduction of PCSK9 and LDL cholesterol with no serious adverse effects. - ALN-TTR02 (Patisiran, LNP-siRNA targeting TTR): Phase II/III; DLinDMA analogue showed 10-fold increase in efficacy in preclinical studies. - CALAA-01 (CDP-based nanoparticle targeting RRM2): first targeted nanoparticulate siRNA delivery system to enter clinical trials; Phase I showed reduction in RRM2 mRNA and presence of specific mRNA cleavage product, supporting RNAi mechanism in humans. - ALN-TTRsc (GalNAc-siRNA conjugate targeting TTR): Phase I showed >90% reduction in serum TTR with 10 mg/kg subcutaneous regular administration, >50% reduction after single 10 mg/kg dose; generally safe and well tolerated. - ARC-520 (DPC targeting HBV): Phase I/II recruiting; latest generation DPCs induced 99% silencing of liver genes in nonhuman primates after single 0.2 mg/kg dose, lasting nearly 7 weeks. - VEGF-A modRNA in mice with myocardial infarction: reduced infarct size and apoptotic cell frequency; ~60% survival at 1 year vs <20% in control. - PSPB modRNA in mice with congenital PSPB deficiency: >80% survival at day 30 vs 0% survival by day 5 in untreated mice. - CDP-siRNA in cynomolgus monkeys: efficacy at 0.6–1.2 mg/kg, tolerability up to 27 mg/kg. - CRISPR-Cas9 corrected hereditary tyrosinemia mutation in adult mice and rescued disease phenotype. - ZFN in vivo gene correction achieved in mouse model of haemophilia using AAV delivery.

Interpretation: Non-viral vectors have made substantial progress, particularly for siRNA delivery, with several formulations showing efficacy in humans. The clinical translation of siRNA delivery systems will help guide development of mRNA and DNA therapeutics. Non-viral delivery of genome editing systems could enable precise and permanent correction of disease genes. The authors conclude that while challenges remain for mRNA and DNA delivery, the efficacy already shown by siRNA formulations in humans, together with preclinical advances, convinces them that non-viral vectors have broad and important potential as therapeutics.

Limitations: Review article; no primary data. - Non-viral vectors generally have low delivery efficiency relative to viral vectors. - DNA delivery requires nuclear transport, a major barrier; mRNA stability is a greater challenge than siRNA because chemical modifications that stabilize siRNA can render mRNA ineffective. - Only ~70% of gene therapy clinical trials use viral vectors; no gene therapeutics approved by FDA (as of writing), though Glybera approved in Europe. - Cationic lipid/polymer toxicity, inflammatory responses, and colloidal instability in physiological fluids. - PEGylation can shield targeting ligands and cause accelerated blood clearance upon repeated administration. - Endosomal escape and intracellular trafficking mechanisms remain poorly understood; ~70% of siRNA taken up by cells undergoes endocytic recycling and exocytosis. - Off-target gene silencing and immunogenicity of nucleic acids. - Limited clinical translation of polymeric and inorganic vectors compared to lipid-based systems. - Long-term safety of integrating systems (transposons) not established. - Need for continued understanding of structure-function relationships and expansion of targetable tissues.